CY1125216T1 - Δομηματα διανομης για διακυτωση και σχετικες μεθοδους - Google Patents
Δομηματα διανομης για διακυτωση και σχετικες μεθοδουςInfo
- Publication number
- CY1125216T1 CY1125216T1 CY20221100326T CY221100326T CY1125216T1 CY 1125216 T1 CY1125216 T1 CY 1125216T1 CY 20221100326 T CY20221100326 T CY 20221100326T CY 221100326 T CY221100326 T CY 221100326T CY 1125216 T1 CY1125216 T1 CY 1125216T1
- Authority
- CY
- Cyprus
- Prior art keywords
- distribution
- related methods
- structures
- methods
- molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756889P | 2018-11-07 | 2018-11-07 | |
| US201962888133P | 2019-08-16 | 2019-08-16 | |
| US201962888238P | 2019-08-16 | 2019-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125216T1 true CY1125216T1 (el) | 2024-12-13 |
Family
ID=70612266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100326T CY1125216T1 (el) | 2018-11-07 | 2022-05-11 | Δομηματα διανομης για διακυτωση και σχετικες μεθοδους |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11027020B2 (https=) |
| EP (2) | EP4083058A3 (https=) |
| JP (2) | JP7516369B2 (https=) |
| KR (1) | KR20210110294A (https=) |
| CN (1) | CN113423722A (https=) |
| AU (1) | AU2019377117B2 (https=) |
| BR (1) | BR112021009003A2 (https=) |
| CA (1) | CA3119060A1 (https=) |
| CL (1) | CL2021001209A1 (https=) |
| CO (1) | CO2021007402A2 (https=) |
| CY (1) | CY1125216T1 (https=) |
| DK (1) | DK3650037T3 (https=) |
| EA (1) | EA202191280A1 (https=) |
| ES (1) | ES2911075T3 (https=) |
| IL (1) | IL282987B2 (https=) |
| MX (1) | MX2021005346A (https=) |
| PL (1) | PL3650037T3 (https=) |
| PT (1) | PT3650037T (https=) |
| SG (1) | SG11202104721RA (https=) |
| TW (1) | TW202031678A (https=) |
| WO (1) | WO2020097394A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CN121513216A (zh) | 2018-03-08 | 2026-02-13 | 应用分子转运公司 | 用于经口递送的毒素衍生的递送构建体 |
| WO2020096695A1 (en) | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Cholix-derived carriers for oral delivery of heterologous payload |
| EP4083058A3 (en) | 2018-11-07 | 2023-01-11 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| KR20230044394A (ko) * | 2020-06-09 | 2023-04-04 | 아이코사백스, 인크. | 바이러스 유사 입자를 제조하는 방법 |
| CN117603361A (zh) * | 2022-08-22 | 2024-02-27 | 复旦大学附属儿科医院 | 包含angptl3单抗的融合蛋白 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US6051405A (en) | 1986-09-24 | 2000-04-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Constructs encoding recombinant antibody-toxin fusion proteins |
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| ATE412009T1 (de) * | 2000-08-24 | 2008-11-15 | Genentech Inc | Methode zur inhibierung von il-22 induziertem pap1 |
| DK1379273T3 (da) | 2000-11-27 | 2009-11-09 | Powderject Vaccines Inc | Nukleinsyreadjuvanser |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| CA2447795A1 (en) | 2001-05-23 | 2002-11-28 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| EP1644415B1 (en) * | 2003-06-23 | 2010-12-01 | Genetics Institute, LLC | Antibodies against interleukin-22 and uses therefor |
| EP1522585A1 (en) | 2003-10-09 | 2005-04-13 | Plant Research International B.V. | Chimeric carrier molecules for the production of mucosal vaccines |
| US20090285771A1 (en) | 2004-10-04 | 2009-11-19 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of macromolecules |
| WO2006135428A2 (en) | 2004-10-04 | 2006-12-21 | Trinity Biosystems, Inc. | Methods and compositions for inducing an immune response against multiple antigens |
| WO2007067597A2 (en) | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
| US8993295B2 (en) | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| US20090092660A1 (en) | 2006-08-09 | 2009-04-09 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of particles |
| US20100143481A1 (en) | 2006-11-08 | 2010-06-10 | Dinesh Shenoy | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
| US8524241B2 (en) | 2007-07-20 | 2013-09-03 | The General Hospital Corporation | Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| WO2009149281A1 (en) | 2008-06-04 | 2009-12-10 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins and uses thereof |
| NO2344540T3 (https=) | 2008-10-02 | 2018-04-28 | ||
| EP3366692A1 (en) * | 2009-06-22 | 2018-08-29 | Amgen, Inc | Refolding proteins using a chemically controlled redox state |
| JP2012533587A (ja) | 2009-07-22 | 2012-12-27 | セニックス バイオサイエンス ゲーエムベーハー | 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| RU2593715C2 (ru) * | 2010-09-15 | 2016-08-10 | Рэндэлл Дж. МРСНИ | Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина |
| US20140065172A1 (en) | 2011-01-26 | 2014-03-06 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| PL2726091T3 (pl) | 2011-06-29 | 2020-08-10 | Rani Therapeutics, Llc | Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek |
| WO2014145016A2 (en) * | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| ES2739129T5 (es) | 2013-11-07 | 2024-04-02 | Memorial Sloan Kettering Cancer Center | IL-22 para uso en el tratamiento de la enfermedad gastrointestinal del injerto contra el huesped |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
| CN106470707A (zh) | 2014-05-07 | 2017-03-01 | 应用分子运输有限责任公司 | 用于口服递送生物活性货物的cholix毒素衍生的融合分子 |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| US20170362291A1 (en) * | 2014-12-23 | 2017-12-21 | Armo Biosciences, Inc. | Methods of Improving Yield in Recombinant Protein Production |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| JP2020513280A (ja) | 2016-12-14 | 2020-05-14 | プロジェニティ， インコーポレイテッド | 消化管疾病の免疫抑制剤による治療 |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| WO2019173787A1 (en) * | 2018-03-08 | 2019-09-12 | Applied Molecular Transport Inc. | Toxin-derived delivery constructs for oral delivery |
| EP4083058A3 (en) | 2018-11-07 | 2023-01-11 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
| US20200140511A1 (en) | 2018-11-07 | 2020-05-07 | Applied Molecular Transport Inc. | Delivery constructs for transcytosis and related methods |
| WO2020096695A1 (en) | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Cholix-derived carriers for oral delivery of heterologous payload |
-
2019
- 2019-11-07 EP EP22159495.5A patent/EP4083058A3/en not_active Withdrawn
- 2019-11-07 EP EP19207825.1A patent/EP3650037B1/en active Active
- 2019-11-07 CA CA3119060A patent/CA3119060A1/en active Pending
- 2019-11-07 PL PL19207825T patent/PL3650037T3/pl unknown
- 2019-11-07 TW TW108140533A patent/TW202031678A/zh unknown
- 2019-11-07 WO PCT/US2019/060356 patent/WO2020097394A1/en not_active Ceased
- 2019-11-07 SG SG11202104721RA patent/SG11202104721RA/en unknown
- 2019-11-07 KR KR1020217017210A patent/KR20210110294A/ko active Pending
- 2019-11-07 AU AU2019377117A patent/AU2019377117B2/en active Active
- 2019-11-07 EA EA202191280A patent/EA202191280A1/ru unknown
- 2019-11-07 CN CN201980088287.9A patent/CN113423722A/zh active Pending
- 2019-11-07 JP JP2021525169A patent/JP7516369B2/ja active Active
- 2019-11-07 ES ES19207825T patent/ES2911075T3/es active Active
- 2019-11-07 DK DK19207825.1T patent/DK3650037T3/da active
- 2019-11-07 MX MX2021005346A patent/MX2021005346A/es unknown
- 2019-11-07 PT PT192078251T patent/PT3650037T/pt unknown
- 2019-11-07 BR BR112021009003-7A patent/BR112021009003A2/pt unknown
-
2020
- 2020-06-15 US US16/902,256 patent/US11027020B2/en active Active
-
2021
- 2021-04-20 US US17/235,567 patent/US20210338828A1/en not_active Abandoned
- 2021-05-06 IL IL282987A patent/IL282987B2/en unknown
- 2021-05-07 CL CL2021001209A patent/CL2021001209A1/es unknown
- 2021-06-07 CO CONC2021/0007402A patent/CO2021007402A2/es unknown
-
2022
- 2022-05-11 CY CY20221100326T patent/CY1125216T1/el unknown
-
2023
- 2023-09-01 US US18/241,744 patent/US20240238429A1/en not_active Abandoned
-
2024
- 2024-07-03 JP JP2024107251A patent/JP2024127939A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2911075T3 (es) | 2022-05-17 |
| JP7516369B2 (ja) | 2024-07-16 |
| MX2021005346A (es) | 2021-10-13 |
| IL282987B (en) | 2022-10-01 |
| CO2021007402A2 (es) | 2021-09-30 |
| CL2021001209A1 (es) | 2021-11-19 |
| AU2019377117A1 (en) | 2021-06-10 |
| AU2019377117B2 (en) | 2025-05-29 |
| WO2020097394A1 (en) | 2020-05-14 |
| EP4083058A2 (en) | 2022-11-02 |
| EA202191280A1 (ru) | 2021-12-27 |
| EP4083058A3 (en) | 2023-01-11 |
| US11027020B2 (en) | 2021-06-08 |
| EP3650037A1 (en) | 2020-05-13 |
| IL282987B2 (en) | 2023-02-01 |
| TW202031678A (zh) | 2020-09-01 |
| JP2022506990A (ja) | 2022-01-17 |
| US20240238429A1 (en) | 2024-07-18 |
| CN113423722A (zh) | 2021-09-21 |
| JP2024127939A (ja) | 2024-09-20 |
| CA3119060A1 (en) | 2020-05-14 |
| US20210338828A1 (en) | 2021-11-04 |
| KR20210110294A (ko) | 2021-09-07 |
| PT3650037T (pt) | 2022-06-27 |
| BR112021009003A2 (pt) | 2021-08-17 |
| DK3650037T3 (da) | 2022-05-02 |
| SG11202104721RA (en) | 2021-06-29 |
| EP3650037B1 (en) | 2022-03-02 |
| IL282987A (en) | 2021-06-30 |
| US20200306383A1 (en) | 2020-10-01 |
| PL3650037T3 (pl) | 2022-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125216T1 (el) | Δομηματα διανομης για διακυτωση και σχετικες μεθοδους | |
| CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| CY1123996T1 (el) | Υποκατεστημενα παραγωγα οξοπυριδινης | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
| CY1125488T1 (el) | Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6 | |
| CY1123623T1 (el) | Θεραπεια νευρολογικων νοσων | |
| BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
| MX2018007288A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| MX392572B (es) | Compuestos del péptido yy (pyy) selectivos y sus usos. | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| MX390120B (es) | Moduladores de la somatostatina y usos de los mismos. | |
| MX378566B (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| MX392259B (es) | ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| MX391392B (es) | ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a. | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| MX2019005657A (es) | Copolimeros de dibloque auto-montados compuestos de pegmema y segmentos polimericos que tienen farmaco. | |
| BR112023018237A2 (pt) | Fenalquilaminas e métodos para fabricação e uso das mesmas | |
| CL2020002038A1 (es) | Oligonucleótidos para modular la expresión de tmem106b. | |
| CL2021002483A1 (es) | Compuestos y composiciones como moduladores de la señalización tlr | |
| SA522431748B1 (ar) | طرق لإنتاج أرجيناز 1 ناتج بمعاودة الارتباط الجيني بشري واستخداماته | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| AU2018275686A1 (en) | Precipitation resistant small molecule drug formulations |